5-year data show TransCon PTH sustains multi-organ benefits and quality of life in hypoparathyroidism patients

Ascendis Pharma announced 5-year Phase 2 trial results for TransCon PTH, showing sustained efficacy and safety in adults with hypoparathyroidism. The treatment replicated natural parathyroid hormone effects, improving kidney function, calcium levels, bone density, and quality of life while reducing dependence on conventional vitamin D and calcium therapy. With 95% of patients completing the trial and no new safety concerns, TransCon PTH shows promise as a new standard of care for this chronic condition. The company plans to continue monitoring and developing this therapy.